Current status and perspectives of therapy for acute myeloid leukemia

Seminars in Hematology

Volumn 38, Issue 3 SUPPL. 6, 2001, Pages 3-9

  Hiddemann, Wolfgang ^a,b   Büchner, Thomas ^a,b,c  

^a German AML Cooperative Group   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CHROMOSOME ABERRATION; CYTOGENETICS; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0034883898     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2001.24262     Document Type: Review

References (18)

1. Acute myeloid leukemia
2. Tailoring the treatment of acute leukemia
3. Four decades of therapy for AML
4. Frequency of prolonged remission duration after highdose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
5. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: Relevance of cytogenetic abnormalities
6. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
7. The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy
8. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly
9. Intensified induction and consolidation with or without maintenance therapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group
10. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
11. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study
12. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia
13. DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer
14. Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16)
15. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12,15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia
16. Management of acute myeloid leukemia in elderly patients
17. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free survival and overall survival when repetitive cycles of high-dose cytarabine are administered
18. Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF